When given with chemotherapy, pembrolizumab shows a benefit in patients with PD-L1-positive TNBC, as seen in the KEYNOTE-355 trial, making it a treatment option for aggressive rare breast cancer subtypes. Here, CD274 is linked to breast cancer.